IDYA IDEAYA Biosciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1676725 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-70.1%
TTM net income YoY-143.0%
TTM EPS YoY-71.4%
Revenue 3-yr CAGR-37.0%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-4,671.1%
Net margin-3,921.1%
FCF margin-3,592.0%
EBITDA margin-4,637.0%
Returns
ROE-32.7%
ROA-31.0%
ROIC (approx.)-35.9%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets5.8%
Debt / equity0.00x
Current ratio14.97x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-3.0%
Payout ratio—
Capex / revenue55.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $10.24M | $8.86M | $6.56M | $10.88M | $207.83M | — | — | $7.00M |
| R&D expense | $121.58M | $82.99M | $95.73M | $86.60M | $82.99M | $74.23M | $70.89M | $140.18M |
| SG&A expense | $26.30M | $22.46M | $19.38M | $18.85M | $16.39M | $14.58M | $13.50M | $10.96M |
| Operating income | -$137.63M | -$122.29M | -$108.54M | -$94.57M | $108.45M | -$88.81M | -$84.39M | -$144.14M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$125.75M | -$112.45M | -$98.54M | -$83.27M | $119.24M | -$77.49M | -$72.18M | -$130.31M |
| EBITDA | -$136.93M | -$121.59M | -$107.86M | -$93.85M | $109.15M | -$88.11M | -$83.79M | -$143.57M |
| EPS (basic) | -1.22 | -1.22 | -1.11 | — | 1.35 | -0.88 | -0.82 | — |
| EPS (diluted) | -1.22 | -1.22 | -1.11 | — | 1.33 | -0.88 | -0.82 | — |
| Weighted avg. shares (diluted) | 102.94M | 92.06M | 88.70M | — | 89.69M | 88.47M | 88.36M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $261.45M | $272.59M | $157.52M | $112.83M | $298.93M | $114.64M | $130.00M | $85.18M |
| Short-term investments | $577.09M | $556.37M | $513.68M | $526.56M | $487.97M | $555.09M | $562.51M | $591.94M |
| Receivables | — | — | — | — | — | — | — | $3,000 |
| Current assets | $871.97M | $864.02M | $696.11M | $666.73M | $802.65M | $685.60M | $707.87M | $689.71M |
| PP&E, net | $7.94M | $8.28M | $8.63M | $8.22M | $8.17M | $8.82M | $8.87M | $8.97M |
| Total assets | $1.22B | $1.31B | $1.03B | $1.11B | $1.19B | $1.04B | $1.10B | $1.12B |
| Current liabilities | $96.41M | $82.68M | $64.83M | $58.81M | $64.51M | $55.34M | $50.85M | $46.07M |
| Total liabilities | $123.96M | $110.79M | $93.08M | $86.39M | $93.10M | $81.62M | $76.51M | $64.94M |
| Shareholders' equity | $1.09B | $1.20B | $937.27M | $1.02B | $1.09B | $959.65M | $1.02B | $1.06B |
| Shares outstanding | 96.65M | 96.38M | 87.86M | 87.80M | 87.67M | 87.64M | 87.57M | 86.50M |
| Cash flow statement | ||||||||
| Operating cash flow | -$93.48M | -$88.21M | -$75.17M | -$90.50M | $142.21M | -$62.47M | -$60.34M | -$121.66M |
| Capital expenditure | $273,000 | $866,000 | $967,000 | $333,000 | $42,000 | $663,000 | $1.33M | $1.10M |
| Free cash flow | -$93.75M | -$89.08M | -$76.14M | -$90.83M | $142.17M | -$63.14M | -$61.67M | -$122.76M |
| Investing cash flow | $78.65M | -$155.93M | $118.95M | -$97.53M | $41.77M | $45.92M | $79.82M | -$197.11M |
| Financing cash flow | $3.69M | $359.21M | $1.18M | $2.13M | $301,000 | $1.21M | $26.14M | $2.75M |
| Depreciation & amortization | $700,000 | $700,000 | $688,000 | $721,000 | $700,000 | $700,000 | $600,000 | $572,000 |
| Stock-based compensation | $17.73M | $16.66M | $14.54M | $11.79M | $12.22M | $11.87M | $10.24M | $9.48M |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.